drugset / Trial / NCT00676403

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

NCT00676403

Phase 2 Completed 137 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

Timeline

Start
2008-04
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 50 mg
Subject Pregabalin Small molecule 100 mg
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 300 mg
Subject Pregabalin Small molecule 450 mg